Literature DB >> 15888513

Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.

William G Honer1, Lili C Kopala, Jonathan Rabinowitz.   

Abstract

Movement disorders in first-episode psychosis are increasingly recognized; however, the prevalence and clinical correlates are uncertain. We compared antipsychotic exposed (< 12 weeks) with nonexposed first-episode patients, and report prevalence as well as clinical and demographic variables associated with extrapyramidal dysfunction. Data are baseline assessments from a multicentre, international drug trial of first-episode psychosis (n = 535). Analysis included the Extrapyramidal Symptom Rating Scale, Premorbid Adjustment Scale, and the Positive and Negative Syndrome Scale. Of non-exposed patients, 28.1% (n = 47/167) had at least one mild sign of extrapyramidal dysfunction, as did 46.3% (n = 169/365) of previously exposed patients. Hypokinetic Parkinsonism was the most prevalent disorder. The severity of movement disorders and negative symptoms were correlated; however, the effect sizes were small. Logistic regression analysis indicated that the salient risk factors for all patients were: previous antipsychotic exposure [odds ratio (OR) = 2.4; 95% confidence interval (CI) 1.6-3.6] and poor premorbid functioning (OR = 1.8; 95% CI 1.2-2.6). For the non-exposed group (n = 167), the significant risk factors were: having severe mental illness in the family (OR = 2.9; 95% CI 1.2-7.2) and poor premorbid functioning (OR = 2.3; 95% CI 1.0-5.3). For the previously exposed group (n = 368), the significant variables were: poor premorbid functioning (OR = 1.8; 95%CI 1.2-2.8) and shorter duration of untreated psychosis (OR = 0.78; 95% CI 0.64-0.94). Although antipsychotic exposure was associated with extrapyramidal signs, the results indicate that many first-episode patients with no exposure to antipsychotics also had extrapyramidal dysfunction. In this group, family history and poor premorbid functioning appear to be associated with increased risk for movement disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888513     DOI: 10.1177/0269881105051539

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  24 in total

1.  Head movements during conversational speech in patients with schizophrenia.

Authors:  Stuart John Leask; Bert Park; Priya Khana; Ben Dimambro
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

2.  Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.

Authors:  Serge Sevy; Delbert G Robinson; Barbara Napolitano; Raman C Patel; Handan Gunduz-Bruce; Rachel Miller; Joanne McCormack; Beth S Lorell; John Kane
Journal:  Schizophr Res       Date:  2010-05-14       Impact factor: 4.939

3.  Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders.

Authors:  Victor Peralta; Virginia Basterra; Maria S Campos; Elena García de Jalón; Lucía Moreno-Izco; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-05-28       Impact factor: 5.270

Review 4.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

5.  Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.

Authors:  Mara Balda; Maria Calvó; Eduardo Padilla; Gonzalo Guerrero; Juan Molina; Nestor V Florenzano; Danielle Kamis; Javier I Escobar; C Robert Cloninger; Gabriel de Erausquin
Journal:  Focus (Am Psychiatr Publ)       Date:  2015

Review 6.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

7.  Unravelling socio-motor biomarkers in schizophrenia.

Authors:  Stephane Raffard; Krasimira Tsaneva-Atanasova; Piotr Słowiński; Francesco Alderisio; Chao Zhai; Yuan Shen; Peter Tino; Catherine Bortolon; Delphine Capdevielle; Laura Cohen; Mahdi Khoramshahi; Aude Billard; Robin Salesse; Mathieu Gueugnon; Ludovic Marin; Benoit G Bardy; Mario di Bernardo
Journal:  NPJ Schizophr       Date:  2017-02-01

8.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

9.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.

Authors:  Jeroen P F Koning; Diederik E Tenback; Jim van Os; André Aleman; René S Kahn; Peter N van Harten
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

10.  Prediction of Neurocognitive Deficits by Parkinsonian Motor Impairment in Schizophrenia: A Study in Neuroleptic-Naïve Subjects, Unaffected First-Degree Relatives and Healthy Controls From an Indigenous Population.

Authors:  Juan L Molina; Gabriela González Alemán; Néstor Florenzano; Eduardo Padilla; María Calvó; Gonzalo Guerrero; Danielle Kamis; Lee Stratton; Juan Toranzo; Beatriz Molina Rangeon; Helena Hernández Cuervo; Mercedes Bourdieu; Manuel Sedó; Sergio Strejilevich; Claude Robert Cloninger; Javier I Escobar; Gabriel A de Erausquin
Journal:  Schizophr Bull       Date:  2016-03-18       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.